SARS-CoV-2 and dialysis: humoral response, clinical and laboratory impacts before vaccination
| Main Author: | |
|---|---|
| Publication Date: | 2024 |
| Other Authors: | , , , , , , , , |
| Format: | Article |
| Language: | eng |
| Source: | Repositório Institucional da FIOCRUZ (ARCA) |
| DOI: | 10.1016/j.bjid.2024.103735 |
| Download full: | https://arca.fiocruz.br/handle/icict/63697 |
Summary: | Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório Brasileiro de Referência em Hepatites Virais. Rio de Janeiro, RJ, Brasil. |
| id |
CRUZ_ca3c7f9fcbedf5c991cc8bb24744cf16 |
|---|---|
| oai_identifier_str |
oai:arca.fiocruz.br:icict/63697 |
| network_acronym_str |
CRUZ |
| network_name_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| repository_id_str |
2135 |
| spelling |
Santos, Alanna CalheirosCosta, Vanessa Duarte daSilva, Lucas Lima daMiguel, Juliana CustódioJardim, RodrigoRivera Dávila, Alberto MartínPaula, Vanessa Salete deMelgaço, Juliana GilLago, Barbara Vieira doVillar, Livia Melo2024-04-25T18:13:15Z2024-04-25T18:13:15Z2024SANTOS, Alanna Calheiros et al. SARS-CoV-2 and dialysis: humoral response, clinical and laboratory impacts before vaccination. Brazilian Journal of Infectious Diseases, v. 28, n. 2, p. 1-9, Mar. 2024.1413-8670https://arca.fiocruz.br/handle/icict/6369710.1016/j.bjid.2024.103735engElsevierSARS-CoV-2 and dialysis: humoral response, clinical and laboratory impacts before vaccinationinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleFundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório Brasileiro de Referência em Hepatites Virais. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório Brasileiro de Referência em Hepatites Virais. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório Brasileiro de Referência em Hepatites Virais. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório Brasileiro de Referência em Hepatites Virais. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Biologia Computacional e de Sistemas. Programa de Pós-Graduação em Biodiversidade e Saúde. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Biologia Computacional e de Sistemas. Programa de Pós-Graduação em Biodiversidade e Saúde. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Virologia Molecular e Parasitologia. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos (Bio-Manguinhos). Laboratório de Tecnologia Imunológica. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório Brasileiro de Referência em Hepatites Virais. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório Brasileiro de Referência em Hepatites Virais. Rio de Janeiro, RJ, Brasil.Patients with kidney disease on Hemodialysis (HD) are susceptible to Coronavirus Disease (COVID-19) due to multiple risk factors. Aim: This study aims to report the prevalence of antibodies against SARS-CoV-2 among patients on hemodialysis before vaccination in Brazil and to compare with clinical, demographic, and laboratory data. Methods: Blood samples from 398 Chronic Kidney Disease (CKD) patients treated in three different private institutions in Rio de Janeiro State, Brazil were submitted to the total antiSARS-CoV-2 testing. Kidney, liver, and hematological markers were also determined. Respiratory samples were tested by real-time PCR for SARS-CoV-2 RNA and positive samples were subjected to high-throughput sequencing on the MinION device. Results: Overall, anti-SARS-CoV-2 prevalence was 54.5 % (217/398) and two individuals had SARS-CoV-2 RNA with variant B.1.1. High anti-SARS-CoV-2 seroprevalence was found in male gender and those with hospital admission in the last 3-months before the inclusion in the study. Lower red blood cell count was observed in the anti-SARS-CoV-2 seropositive group. High levels of anti-SARS-CoV-2 were found in those who reported symptoms, had low levels of eosinophils and low hematocrit, and who practiced physical activity. Conclusion: High prevalence of anti-SARS-CoV-2 was found in CKD patients before the universal immunization in Brazil suggesting that dialysis patients were highly exposed to SARS-CoV-2.SARS-CoV-2PrevalenceChronic kidney diseaseSeroepidemiologyCOVID-19Pandemicinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-82991https://arca.fiocruz.br/bitstreams/33fec141-43f7-4978-8279-22eb112f06db/download5a560609d32a3863062d77ff32785d58MD51falseAnonymousREADORIGINALva_Santos_Alanna Calheiros_etal_biomanguinhos_2024.pdfva_Santos_Alanna Calheiros_etal_biomanguinhos_2024.pdfapplication/pdf592703https://arca.fiocruz.br/bitstreams/6b685f17-42fc-4389-8bd0-00e88e4183b2/download81a93f8504b4ac0443cb0a0ff5420816MD52trueAnonymousREADTEXTva_Santos_Alanna Calheiros_etal_biomanguinhos_2024.pdf.txtva_Santos_Alanna Calheiros_etal_biomanguinhos_2024.pdf.txtExtracted texttext/plain51739https://arca.fiocruz.br/bitstreams/5e713c23-fe85-41b7-8c36-50162d68e7bf/download474ad3dc9a0778b2b6c9684815582158MD55falseAnonymousREADTHUMBNAILva_Santos_Alanna Calheiros_etal_biomanguinhos_2024.pdf.jpgva_Santos_Alanna Calheiros_etal_biomanguinhos_2024.pdf.jpgGenerated Thumbnailimage/jpeg5707https://arca.fiocruz.br/bitstreams/90ef7b88-f75f-43da-8367-35f738bc80f1/download4b8ae9fa7840d4a9a0a8dcfb63503d82MD56falseAnonymousREADicict/636972025-07-29 23:26:29.329open.accessoai:arca.fiocruz.br:icict/63697https://arca.fiocruz.brRepositório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352025-07-30T02:26:29Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)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 |
| dc.title.none.fl_str_mv |
SARS-CoV-2 and dialysis: humoral response, clinical and laboratory impacts before vaccination |
| title |
SARS-CoV-2 and dialysis: humoral response, clinical and laboratory impacts before vaccination |
| spellingShingle |
SARS-CoV-2 and dialysis: humoral response, clinical and laboratory impacts before vaccination Santos, Alanna Calheiros SARS-CoV-2 Prevalence Chronic kidney disease Seroepidemiology COVID-19 Pandemic |
| title_short |
SARS-CoV-2 and dialysis: humoral response, clinical and laboratory impacts before vaccination |
| title_full |
SARS-CoV-2 and dialysis: humoral response, clinical and laboratory impacts before vaccination |
| title_fullStr |
SARS-CoV-2 and dialysis: humoral response, clinical and laboratory impacts before vaccination |
| title_full_unstemmed |
SARS-CoV-2 and dialysis: humoral response, clinical and laboratory impacts before vaccination |
| title_sort |
SARS-CoV-2 and dialysis: humoral response, clinical and laboratory impacts before vaccination |
| author |
Santos, Alanna Calheiros |
| author_facet |
Santos, Alanna Calheiros Costa, Vanessa Duarte da Silva, Lucas Lima da Miguel, Juliana Custódio Jardim, Rodrigo Rivera Dávila, Alberto Martín Paula, Vanessa Salete de Melgaço, Juliana Gil Lago, Barbara Vieira do Villar, Livia Melo |
| author_role |
author |
| author2 |
Costa, Vanessa Duarte da Silva, Lucas Lima da Miguel, Juliana Custódio Jardim, Rodrigo Rivera Dávila, Alberto Martín Paula, Vanessa Salete de Melgaço, Juliana Gil Lago, Barbara Vieira do Villar, Livia Melo |
| author2_role |
author author author author author author author author author |
| dc.contributor.author.fl_str_mv |
Santos, Alanna Calheiros Costa, Vanessa Duarte da Silva, Lucas Lima da Miguel, Juliana Custódio Jardim, Rodrigo Rivera Dávila, Alberto Martín Paula, Vanessa Salete de Melgaço, Juliana Gil Lago, Barbara Vieira do Villar, Livia Melo |
| dc.subject.en.none.fl_str_mv |
SARS-CoV-2 Prevalence Chronic kidney disease Seroepidemiology COVID-19 Pandemic |
| topic |
SARS-CoV-2 Prevalence Chronic kidney disease Seroepidemiology COVID-19 Pandemic |
| description |
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório Brasileiro de Referência em Hepatites Virais. Rio de Janeiro, RJ, Brasil. |
| publishDate |
2024 |
| dc.date.accessioned.fl_str_mv |
2024-04-25T18:13:15Z |
| dc.date.available.fl_str_mv |
2024-04-25T18:13:15Z |
| dc.date.issued.fl_str_mv |
2024 |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.citation.fl_str_mv |
SANTOS, Alanna Calheiros et al. SARS-CoV-2 and dialysis: humoral response, clinical and laboratory impacts before vaccination. Brazilian Journal of Infectious Diseases, v. 28, n. 2, p. 1-9, Mar. 2024. |
| dc.identifier.uri.fl_str_mv |
https://arca.fiocruz.br/handle/icict/63697 |
| dc.identifier.issn.none.fl_str_mv |
1413-8670 |
| dc.identifier.doi.none.fl_str_mv |
10.1016/j.bjid.2024.103735 |
| identifier_str_mv |
SANTOS, Alanna Calheiros et al. SARS-CoV-2 and dialysis: humoral response, clinical and laboratory impacts before vaccination. Brazilian Journal of Infectious Diseases, v. 28, n. 2, p. 1-9, Mar. 2024. 1413-8670 10.1016/j.bjid.2024.103735 |
| url |
https://arca.fiocruz.br/handle/icict/63697 |
| dc.language.iso.fl_str_mv |
eng |
| language |
eng |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
Elsevier |
| publisher.none.fl_str_mv |
Elsevier |
| dc.source.none.fl_str_mv |
reponame:Repositório Institucional da FIOCRUZ (ARCA) instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
| instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
| instacron_str |
FIOCRUZ |
| institution |
FIOCRUZ |
| reponame_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| collection |
Repositório Institucional da FIOCRUZ (ARCA) |
| bitstream.url.fl_str_mv |
https://arca.fiocruz.br/bitstreams/33fec141-43f7-4978-8279-22eb112f06db/download https://arca.fiocruz.br/bitstreams/6b685f17-42fc-4389-8bd0-00e88e4183b2/download https://arca.fiocruz.br/bitstreams/5e713c23-fe85-41b7-8c36-50162d68e7bf/download https://arca.fiocruz.br/bitstreams/90ef7b88-f75f-43da-8367-35f738bc80f1/download |
| bitstream.checksum.fl_str_mv |
5a560609d32a3863062d77ff32785d58 81a93f8504b4ac0443cb0a0ff5420816 474ad3dc9a0778b2b6c9684815582158 4b8ae9fa7840d4a9a0a8dcfb63503d82 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ) |
| repository.mail.fl_str_mv |
repositorio.arca@fiocruz.br |
| _version_ |
1839716212985036800 |